Baker Avenue Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Baker Avenue Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324K	Buy	+653	New	+$289K	0.01%	660
2023 Q4	–	Sell	-63	Closed	-$21.9K	–	1471
2023 Q3	$21.9K	Buy	63 +1	+2%	+$350	﹤0.01%	641
2023 Q2	$21.8K	Sell	62 -7	-10%	-$2.36K	﹤0.01%	632
2023 Q1	$21.7K	Sell	69 -1,591	-96%	-$477K	﹤0.01%	650
2022 Q4	$479K	Sell	1,660 -59	-3%	-$18K	0.03%	250
2022 Q3	$498K	Buy	+1,719	New	+$495K	0.03%	236
2021 Q1	–	Sell	-2,238	Closed	-$528K	–	256
2020 Q4	$528K	Sell	2,238 -3,534	-61%	-$811K	0.04%	168
2020 Q3	$1.57M	Buy	5,772 +677	+13%	+$187K	0.12%	98
2020 Q2	$1.48M	Sell	5,095 -331	-6%	-$89.7K	0.12%	99
2020 Q1	$1.29M	Sell	5,426 -596	-10%	-$137K	0.15%	64
2019 Q4	$1.32M	Sell	6,022 -1,693	-22%	-$343K	0.1%	132
2019 Q3	$1.31M	Buy	7,715 +539	+8%	+$95.4K	0.1%	118
2019 Q2	$1.31M	Buy	7,176 +241	+3%	+$42.1K	0.11%	121
2019 Q1	$1.27M	Buy	+6,935	New	+$1.28M	0.11%	122
2016 Q4	–	Sell	-5,570	Closed	-$486K	–	210
2016 Q3	$486K	Buy	+5,570	New	+$526K	0.07%	140

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baker Avenue Asset Management's VRTX Position: Q2 2026 in Review

Baker Avenue Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 653 shares worth $324K. The stake represents 0.01% of the portfolio and ranks #660 among its holdings. This is a return to the name: Baker Avenue Asset Management previously reported a position in VRTX as recently as Q3 2023.

Baker Avenue Asset Management first reported a position in VRTX in Q3 2016 and has held it in 15 quarters since. The position peaked at $1.57M in Q3 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Baker Avenue Asset Management held 653 shares of Vertex Pharmaceuticals worth $324K as of Q2 2026.
Vertex Pharmaceuticals was a new Baker Avenue Asset Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #660 holding.
Baker Avenue Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 15 quarters since.
Baker Avenue Asset Management's Vertex Pharmaceuticals position peaked at $1.57M in Q3 2020.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.